PH FDC SC: Clinical Trials

3 completed, 1 recruiting. 3 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer Giredestrant, Abemaciclib, Ipatasertib - Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer	Phase 1 / Phase 2	Recruiting	Hoffmann-La Roche	316	2021-06-22	2026-11-03
A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response Entrectinib, Inavolisib, Alectinib - Advanced Unresectable or Metastatic Solid Malignancy	Phase 2	Completed	Genentech, Inc.	252	2021-01-13	2025-01-08
A Two-Arm Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Chinese Participants With HER2-Positive Early Breast Cancer Pertuzumab IV, Trastuzumab IV, Pertuzumab and Trastuzumab FDC SC - HER2-positive Early Breast Cancer	Phase 3	Completed	Hoffmann-La Roche	200	2020-02-05	2026-02-20
A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC), Pertuzumab IV, Trastuzumab IV - HER2-Positive Early Breast Cancer	Phase 2	Completed	Hoffmann-La Roche	160	2018-12-19	2024-01-02